Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabigatran Etexilate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 19/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.77 |
| ▸ | NQO2 | P16083 | 2/20 | 0.76 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 1/20 | 0.63 |
| ▸ | PLG | P00747 | 1/20 | 0.63 |
| ▸ | PLAT | P00750 | 1/20 | 0.63 |
| ▸ | PROC | P04070 | 1/20 | 0.63 |
| ▸ | HPN | P05981 | 1/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781620 | 1.00 | F2 (0.77) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL4288129 | 0.99 | F2 (0.76) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL3576423 | 0.99 | F2 (0.76) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL6517210 | 0.99 | F2 (0.76) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL1268805 | 0.98 | F2 (0.74) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL2525835 | 0.97 | F2 (0.73) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL2525834 | 0.97 | F2 (0.73) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6775505 | 0.96 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6781399 | 0.96 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6781408 | 0.96 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485094-B2 | DOSAGE FORM FOR ORAL ADMINISTRATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO] PROPIONIC ACID ETHYL ESTER OR ITS SALTS | BOEHRINGER INGELHEIM INT (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20200085807-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | BOEHRINGER INGELHEIM INT (DE) | 2020-03-19 | — | — | US | claimed |
| US-20190231766-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-01 | — | — | US | claimed |
| US-20180221359-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | BOEHRINGER INGELHEIM INT (DE) | 2018-08-09 | — | — | US | claimed |
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | claimed |
| US-9925174-B2 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | claimed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | claimed |
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| US-20150005350-A1 | ADMINISTRATION OF ETHYL 3-[(2--1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-01 | — | — | US | claimed |
| US-20130289248-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | claimed |
| US-20060276513-A1 | Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-07 | — | — | US | claimed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | claimed |
| US-20060183779-A1 | ADMINISTRATION FORM FOR THE ORAL APPLICATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER AND THE SALTS THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-08-17 | — | — | US | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| US-20050234104-A1 | Dabigatran etexilate mesylate polymorph, crystalline form of a prodrug used for post-operative prophylaxis of deep vein thrombosis and the prevention of a stroke; stability; solubility; reproduciblity; hydrophobic; pharmacological potency; low amorphization during grinding and compression | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-20050107438-A1 | Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | claimed |
| US-20050038077-A1 | Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | US | claimed |
| US-20050014770-A1 | Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20030181488-A1 | Dabigatran etexilate or its methanesulfonate salt; water solubility, treating deep-vein thrombosis; pellelization; bioavailability, drug delivery | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-25 | — | — | US | claimed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085807-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | CHRM3, CHRM5, CHRM4 | F2 2256/4885NR1I2 185/4885ADORA3 409/4885 |
| US-20050107438-A1 | Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore | SLCO4C1, SLCO1B3, SLCO1B1 | F2 2345/4885NR1I2 321/4885ADORA3 341/4885 |
| US-20050038077-A1 | Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof | PIR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 | F2 1003/4885NR1I2 2085/4885ADORA3 429/4885 |
| US-20060276513-A1 | Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | OPRM1, HTR3C, HTR3A | F2 421/4885NR1I2 42/4885ADORA3 117/4885 |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | F2 6/4885NR1I2 2105/4885ADORA3 108/4885 |
| US-20130289248-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | F2 6/4885NR1I2 2105/4885ADORA3 108/4885 |
| US-20180221359-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | CHRM3, CHRM5, CHRM4 | F2 2256/4885NR1I2 185/4885ADORA3 409/4885 |
| US-20050234104-A1 | Dabigatran etexilate mesylate polymorph, crystalline form of a prodrug used for post-operative prophylaxis of deep vein thrombosis and the prevention of a stroke; stability; solubility; reproduciblity; hydrophobic; pharmacological potency; low amorphization during grinding and compression | CYP2C9, CYP3A4, CYP2C19 | F2 13/4885NR1I2 397/4885ADORA3 220/4885 |
| US-20050014770-A1 | Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | PTAFR, PLAT, MPL | F2 38/4885NR1I2 1421/4885ADORA3 304/4885 |
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | AZI2, IL4I1, ABAT | F2 4142/4885NR1I2 2137/4885ADORA3 2620/4885 |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | PROC, F12, SERPINC1 | F2 4/4885NR1I2 419/4885ADORA3 838/4885 |
| US-20150005350-A1 | ADMINISTRATION OF ETHYL 3-[(2--1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | CHRM3, PLPBP, FABP2 | F2 2210/4885NR1I2 119/4885ADORA3 834/4885 |
| US-20060183779-A1 | ADMINISTRATION FORM FOR THE ORAL APPLICATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER AND THE SALTS THEREOF | FABP2, SLC16A1, SLC16A3 | F2 1405/4885NR1I2 238/4885ADORA3 339/4885 |
| US-20190231766-A1 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | CHRM3, CHRM5, CHRM4 | F2 2256/4885NR1I2 185/4885ADORA3 409/4885 |
| US-20030181488-A1 | Dabigatran etexilate or its methanesulfonate salt; water solubility, treating deep-vein thrombosis; pellelization; bioavailability, drug delivery | SELP, PLG, TFPI | F2 10/4885NR1I2 977/4885ADORA3 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.